Parnell Expands Anesthesia Suite with Strategic Sevoflurane Launch

OVERLAND PARK, KS – June 03, 2026 – Veterinary pharmaceutical company Parnell has announced a significant expansion of its anesthesia portfolio with the launch of Sevoflurane Inhalation Anesthetic. The move positions the company to offer a more comprehensive suite of products for veterinary practices, aiming to become a single, accountable partner for the entire anesthetic workflow. By adding a competitively priced sevoflurane option, Parnell is addressing a critical need for cost-effective, reliable solutions in a market facing both rising operational expenses and increasing client sensitivity to costs.

Indicated for the induction and maintenance of general anesthesia in dogs, the new product joins Parnell’s existing offerings, including PropofolVet Multidose, Isoflurane, and reversal agents. This strategic addition underscores a broader trend in the animal health industry, where companies are building integrated ecosystems of products and services to create deeper, more resilient partnerships with veterinary clinics.

A Calculated Move in a Growing Market

Parnell’s entry into the sevoflurane space is a well-timed maneuver within the burgeoning veterinary anesthesia market. The global market for these drugs is on a steep growth trajectory, projected to climb from approximately $545 million in 2026 to over $852 million by 2033. The specific segment for inhalation anesthetics is even more robust, valued at over $1.2 billion in 2024 and expected to double to $2.42 billion by 2033, expanding at a compound annual growth rate of 8.1%. This growth is fueled by rising pet ownership and an increasing demand for more sophisticated veterinary procedures.

By launching its own sevoflurane, Parnell is directly challenging established players like Abbott Laboratories, Baxter, and Piramal Pharma Solutions in a market segment where generic formulations are dominant, capturing over 58% of the market in 2025. While isoflurane has long been a staple in veterinary clinics due to its lower upfront cost, sevoflurane is noted for its rapid induction and recovery profile. This clinical advantage has made it a preferred choice in many settings, despite historically higher prices. Parnell's strategy appears to be leveraging the clinical preference for sevoflurane while mitigating the cost barrier through competitive pricing, aiming to capture a significant share of the North American market, which currently accounts for over 42% of global veterinary anesthesia sales.

Redefining Value for the Modern Veterinary Practice

The company’s claim of offering a “competitively priced” option is central to its value proposition. Historically, the price gap between sevoflurane and isoflurane was substantial, with some reports from a decade ago showing sevoflurane at nearly ten times the cost. While that gap has narrowed, with current sevoflurane prices for a 250 mL bottle ranging from $82 to over $120, cost remains a key consideration for practice managers. Parnell's move to offer an affordable version taps into a critical need for budget control without compromising clinical quality.

Beyond the sticker price, the true value may lie in operational efficiency. The faster recovery times associated with sevoflurane can translate into reduced staff monitoring time and quicker patient turnover, providing indirect cost savings that can offset the higher initial drug expense. This aligns with the broader push in veterinary medicine for more efficient workflow management. Furthermore, by positioning itself as a “single source” for a complete anesthesia toolkit, Parnell is offering a streamlined procurement process. For a busy veterinary practice, consolidating vendors for injectables, inhalants, and reversal agents can simplify inventory management, reduce administrative burden, and ensure product compatibility. This single-partner approach fosters accountability and simplifies support, a significant advantage when dealing with critical procedures like anesthesia.

Beyond the Bottle: An Ecosystem of Product and Education

Perhaps the most forward-thinking aspect of Parnell's strategy is its integration of product delivery with professional development. The launch is supported by the company’s “Foundations of Anesthesia & Sedation Certificate Program,” an online course offering 10 RACE-approved continuing education hours. This initiative is designed to build competency and confidence across the entire veterinary team, from seasoned veterinarians to newer technicians.

“Veterinary professionals place immense trust in the products they use during anesthesia, and that responsibility drives everything we do,” stated Pablo Lamberto, DVM, U.S. General Manager at Parnell. “In a category where consistency and reliability matter as much as cost, the addition of Sevoflurane allows us to better support clinics with dependable, high-quality options across the entire anesthesia protocol.”

This dual focus on providing high-quality, nonflammable anesthetics while simultaneously investing in the skills of the professionals who use them creates a powerful support ecosystem. It demonstrates an understanding that patient safety and successful outcomes depend not only on the quality of the pharmaceuticals but also on the proficiency of the team administering them. By bundling a comprehensive product portfolio with accessible, high-quality education, the company is not just selling a product; it is selling confidence and a higher standard of care. This holistic approach helps practices mitigate risks, empower their staff, and ultimately deliver better patient outcomes, solidifying Parnell’s role as a strategic partner rather than just a supplier.